citalopram has been researched along with Adjustment Disorder in 3 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Excerpt | Relevance | Reference |
---|---|---|
"Citalopram is a bicyclic phtalane derivative." | 2.66 | Clinical and biochemical effects of citalopram, a selective 5-HT reuptake inhibitor--a dose-response study in depressed patients. ( Bjerkenstedt, L; Edman, G; Flyckt, L; Hagenfeldt, L; Sedvall, G; Wiesel, FA, 1985) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (33.33) | 18.7374 |
1990's | 1 (33.33) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Shear, MK | 1 |
Reynolds, CF | 1 |
Simon, NM | 1 |
Zisook, S | 1 |
Wang, Y | 1 |
Mauro, C | 1 |
Duan, N | 1 |
Lebowitz, B | 1 |
Skritskaya, N | 1 |
Hofmann, M | 1 |
Vidoni, F | 1 |
Bjerkenstedt, L | 1 |
Edman, G | 1 |
Flyckt, L | 1 |
Hagenfeldt, L | 1 |
Sedvall, G | 1 |
Wiesel, FA | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Web Based Therapist and Patient Tutorials on Prolonged Grief. Study 2[NCT05575817] | 34 participants (Actual) | Interventional | 2022-10-01 | Active, not recruiting | |||
Web Based Therapist and Patient Tutorials on Prolonged Grief. Study 1[NCT05121792] | 400 participants (Actual) | Interventional | 2021-10-28 | Completed | |||
Optimizing Treatment for Complicated Grief (Healing Emotions After Loss:HEAL)[NCT01179568] | Phase 2 | 395 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The 19-item self-report instrument assesses symptoms of complicated grief. Responses on individual items are added up to a total score, which can range from 0 to 76 with higher scores indicating more intense symptoms. This scale has been utilized previously in treatment studies of CG. Additional times points include weeks 4, 8, 12, 16, 20 and 40. For the pre-specified analyses we compared change in the ICG total score from baseline (calculated as baseline score minus week 12 score) for CIT vs PLA at week 12 (aim 1), based on the intention-to-treat principle including all randomized participants. (NCT01179568)
Timeframe: Baseline and week 12
Intervention | score change from baseline to wk12 (Mean) |
---|---|
Citalopram (CIT) | 18 |
Placebo (PLA; Sugar Pill) | 16 |
The 19-item self-report instrument assesses symptoms of complicated grief. Responses on individual items are added up to a total score, which can range from 0 to 76 with higher scores indicating more intense symptoms. This scale has been utilized previously in treatment studies of CG. Additional times points include weeks 4, 8, 12, 16, 20 and 40. For the pre-specified analyses we compared change in the ICG total score from baseline (calculated as baseline score minus week 20 score) for CIT with CGT vs PLA with CGT (aim 2), and for CIT with CGT vs CIT (aim 3) based on the intention-to-treat principle including all randomized participants. (NCT01179568)
Timeframe: Baseline and week 20
Intervention | score change from baseline to wk20 (Mean) |
---|---|
Citalopram (CIT) | 20 |
Complicated Grief Treatment With Citalopram (CGT With CIT) | 25 |
Complicated Grief Treatment With Placebo (CGT With PLA) | 26 |
The WSAS is a modification of a scale introduced by Hafner and Marks (1976), consisting of 0-8 point ratings of the extent to which symptoms interfere with five areas of daily functioning: work, home management, private leisure, social leisure, and family relationships. It is a well-validated, widely used self-report measure. Additional time points include weeks 4, 8, 12, 16, and 40. A total score calculated as a sum of all items (possible range 0-40) was used in the analyses with higher scores indicating more impairment. For the pre-specified analyses we compared change in the WSAS total score from baseline (calculated as baseline score minus week 12 score) for CIT vs PLA at week 12 (aim 1), based on the intention-to-treat principle including all randomized participants. (NCT01179568)
Timeframe: Baseline and week 12
Intervention | score change from baseline to wk12 (Mean) |
---|---|
Citalopram (CIT) | 10 |
Placebo (PLA; Sugar Pill) | 8 |
The WSAS is a modification of a scale introduced by Hafner and Marks (1976), consisting of 0-8 point ratings of the extent to which symptoms interfere with five areas of daily functioning: work, home management, private leisure, social leisure, and family relationships. It is a well-validated, widely used self-report measure. Additional time points include weeks 4, 8, 12, 16, and 40. A total score calculated as a sum of all items (possible range 0-40) was used in the analyses with higher scores indicating more impairment. For the pre-specified analyses we compared change in the WSAS total score from baseline (calculated as baseline score minus week 20 score) for CIT with CGT vs PLA with CGT (aim 2), and for CIT with CGT vs CIT (aim 3) based on the intention-to-treat principle including all randomized participants. (NCT01179568)
Timeframe: Baseline and week 20
Intervention | score change from baseline to wk20 (Mean) |
---|---|
Citalopram (CIT) | 10 |
Complicated Grief Treatment With Citalopram (CGT With CIT) | 14 |
Complicated Grief Treatment With Placebo (CGT With PLA) | 16 |
Brief rating scale frequently used in clinical trials. For this study, version modified for complicated grief was be used. Response is defined as a score of 1(very much improved) or 2 (much improved) on the scale. The rating was done by an Independent Evaluator. (NCT01179568)
Timeframe: Weeks 12 and 20
Intervention | percentage of responders (Number) |
---|---|
Citalopram (CIT) | 46 |
Placebo (PLA; Sugar Pill) | 38 |
Complicated Grief Treatment With Citalopram (CGT With CIT) | 84 |
Complicated Grief Treatment With Placebo (CGT With PLA) | 83 |
2 trials available for citalopram and Adjustment Disorder
Article | Year |
---|---|
Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial.
Topics: Adjustment Disorders; Adult; Aged; Citalopram; Combined Modality Therapy; Comorbidity; Depressive Di | 2016 |
Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial.
Topics: Adjustment Disorders; Adult; Aged; Citalopram; Combined Modality Therapy; Comorbidity; Depressive Di | 2016 |
Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial.
Topics: Adjustment Disorders; Adult; Aged; Citalopram; Combined Modality Therapy; Comorbidity; Depressive Di | 2016 |
Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial.
Topics: Adjustment Disorders; Adult; Aged; Citalopram; Combined Modality Therapy; Comorbidity; Depressive Di | 2016 |
Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial.
Topics: Adjustment Disorders; Adult; Aged; Citalopram; Combined Modality Therapy; Comorbidity; Depressive Di | 2016 |
Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial.
Topics: Adjustment Disorders; Adult; Aged; Citalopram; Combined Modality Therapy; Comorbidity; Depressive Di | 2016 |
Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial.
Topics: Adjustment Disorders; Adult; Aged; Citalopram; Combined Modality Therapy; Comorbidity; Depressive Di | 2016 |
Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial.
Topics: Adjustment Disorders; Adult; Aged; Citalopram; Combined Modality Therapy; Comorbidity; Depressive Di | 2016 |
Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial.
Topics: Adjustment Disorders; Adult; Aged; Citalopram; Combined Modality Therapy; Comorbidity; Depressive Di | 2016 |
Clinical and biochemical effects of citalopram, a selective 5-HT reuptake inhibitor--a dose-response study in depressed patients.
Topics: Adjustment Disorders; Adolescent; Adult; Aged; Amino Acids; Antidepressive Agents; Biogenic Amines; | 1985 |
1 other study available for citalopram and Adjustment Disorder
Article | Year |
---|---|
[SSRI-induced akathesia].
Topics: Adjustment Disorders; Akathisia, Drug-Induced; Alprazolam; Anti-Anxiety Agents; Antidepressive Agent | 1996 |